Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
December 2011, Vol 2, No 7
December 2011, Vol 2, No 7
High-Dose Radiation Does Not Improve Survival in Stage III NSCLC
By
Phoebe Starr
ASTRO Annual Meeting
December 2011, Vol 2, No 7
Read Article
Reporting Gap for Near-Misses and Errors in Radiation Oncology Is Rampant
By
Phoebe Starr
ASTRO Annual Meeting
December 2011, Vol 2, No 7
Read Article
Azacitidine Treatment Failure Outcomes in Patients with MDS or AML
In the Literature
December 2011, Vol 2, No 7
Azacitidine is the current standard of care for high-risk myelodysplastic syndrome (MDS), but many patients experience treatment failure. No study has previously analyzed patient outcomes of those who fail azacitidine therapy. This new analysis combined data from 4 international clinical trials to describe patient outcomes after failing azacitidine treatment (Prébet T, et al. J Clin Oncol. 2011;29:3322-3327).
Read Article
Second-Generation TKIs Produce Faster Optimal Response than Imatinib in CML
In the Literature
December 2011, Vol 2, No 7
The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib produce optimal cytogenetic response after 3 months of treatment in themajority of patients with chronic myeloid leukemia (CML) in the chronic phase, a much faster rate than the 12 to 18 months for the peaked response reported with imatinib (Jabbour E, et al. J Clin Oncol. 2011;29:4260-4266).
Read Article
Letrozole More Effective than Tamoxifen in Postmenopausal Breast Cancer
In the Literature
December 2011, Vol 2, No 7
Read Article
Bortezomib–Rituximab Combo Improves PFS in Relapsed Follicular Lymphoma
In the Literature
December 2011, Vol 2, No 7
A phase 3 study comparing the efficacy and safety of rituximab alone and in combination with bortezomib in patients with relapsed grade 1 or 2 follicular lymphoma who were rituximab- naive or rituximab-sensitive showed extended PFS with the drug combination comparedwith rituximab alone (Coiffier B, et al. Lancet Oncol. 2011;12:773-784).
Read Article
Axitinib Promising Second-Line Treatment for Advanced Renal Carcinoma
In the Literature
December 2011, Vol 2, No 7
This is the first phase 3 clinical trial to compare the effectiveness of 2 second- generation antiangiogenic agents —axitinib and sorafenib—for meta - static renal-cell cancer, showing great promise for the investigational drug axitinib (Rini BI, et al. Lancet. 2011;378: 1931-1939).
Read Article
Young Patients Are Served Equally Well by Lumpectomy or Mastectomy
By
Caroline Helwick
ASCO Breast Cancer Symposium
December 2011, Vol 2, No 7
Breast cancer in women under age 40 years is often considered a more aggressive disease than in older women, and this often leads clinicians to recommend mastectomy over breast-conserving therapy (BCT), that is, lumpectomy or radiation. However, 2 studies presented at the 2011 Breast Cancer Symposium suggest that younger age in itself is not a reason for mastectomy.
Read Article
Delivering Affordable, Evidence-Based Cancer Care in High-Income Countries
By
Caroline Helwick
ESMO 2011 Conference
,
ESMO
December 2011, Vol 2, No 7
A consortium of world cancer specialists, economists, and policymakers is tackling the issue of equitable cancer care in the face of rising cost of care in high-income countries.
Read Article
Thromboembolism after Chemotherapy Raises Healthcare Costs about 30%
By
Caroline Helwick
ESMO 2011 Conference
,
ESMO
December 2011, Vol 2, No 7
The development of venous thromboembolism (VTE) in patients with cancer has a significant impact in terms of morbidity and mortality and healthcare costs, according to a “real-world analysis” reported at the 2011 European Multi - disciplinary Cancer Congress.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma